A Phase I Trial of Oral Metronomic Topotecan in Combination With Oral Pazopanib Utilizing a Daily Dosing Schedule to Treat Recurrent or Persistent Gynecologic Tumors
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Pazopanib (Primary) ; Topotecan (Primary)
- Indications Cervical cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 12 Apr 2016 Status changed from active, no longer recruiting to completed.
- 10 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
- 01 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.